NV-RHINOSTICS
28.9.2021 14:02:12 CEST | Business Wire | Press release
Hamilton Company and Rhinostics, an early-stage Harvard University spin-out company, are combining their respective strengths to improve the speed and quality of nasal and nasopharyngeal sample workflows from collection to processing while also reducing the need for active labor involvement. This sample type is widely used to detect antibodies and antigens in relation to the novel coronavirus, SARS-CoV-2 and many other pathogens.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005022/en/
The hands-free automated workflow includes use of the RHINOstic™ nasal swab collection device and one of Hamilton’s Microlab® STAR™ , Microlab NIMBUS® , or Microlab Prep™ automated liquid handling workstations, along with the LabElite® DeCapper from Hamilton Storage Technologies. This combination of technologies alleviates common time-consuming bottlenecks in testing workflows, even during times of surging sample influx. By increasing sample throughput and reducing turnaround times, stakeholders are empowered and informed to make confident downstream decisions regarding patient treatment strategies.
The patent-pending RHINOstic nasal and buccal swab collection device consists of a polypropylene swab stick, integrated into an automation-friendly cap, and a transport tube labeled with a 2-dimensional (2D) barcode. At the point of collection, the swab minimizes patient discomfort when gathering sample. Samples collected via the RHINOstic may be shipped without use of viral transport media (VTM) to reduce reagent costs and risks of leaking or aerosol creation. Lack of VTM also eliminates the need to concentrate samples prior to analysis.
Up to 96 samples may be automatically accessioned and decapped at once using the LabElite DeCapper with a 12-channel head and conversion kit. The LabElite DeCapper may be used as a standalone device or integrated with Hamilton’s automated liquid handlers.
Hamilton’s automated liquid handlers consistently and automatically perform tedious and time-consuming pipetting and other tasks so that users may attend to higher value tasks. By reducing active labor time, efficiency and productivity are increased across the laboratory. Walkaway operation also reduces the user’s risk of biohazard exposure.
Each Hamilton automated liquid handler may be optimized with tools and programmed methods for the application at hand, including PCR, next generation sequencing (NGS), ELISA and more. User-friendly software guides any user through assay setup and processing, and when used with Hamilton pipette tips, patented Compressed O-Ring Expansion (CO-RE® ) technology creates a tight seal between pipetting mandrel and tip to support highly accurate and consistent results.
Automated sample processing using this hands-free automated workflow from Hamilton and Rhinostics may be easily scaled at any time without increasing labor, equipment or reagent costs.
About Hamilton Company:
Hamilton Company is a global enterprise with affiliates in Reno, Nevada; Franklin, Massachusetts (both USA); and Bonaduz, Switzerland and sales offices throughout the world. Hamilton Company and its affiliated entities are an industry leader in the design and manufacture of liquid handling, process analytics, robotics and automated storage solutions. For more than 60 years, Hamilton Company has been satisfying customer needs by combining quality materials with skilled workmanship to ensure the highest level of performance. Hamilton Company’s lifelong commitment to precision and quality has earned us global ISO 9001 Certification. For more information, visit www.hamiltoncompany.com .
About Rhinostics:
Rhinostics Inc. is an early stage company commercializing a simple and elegant solution to bring efficiencies and cost savings to the laboratory workflow. The RHINOstic nasal swab provides features that increase sample throughput by more than 10-fold while removing labor and errors from the laboratory workflow. The swab is integrated onto a cap that can be automated for removal from the tube while all 96 samples are simultaneously accessioned through scanning a 2D barcode on the bottom of the tubes. Additionally, the device allows dry shipment of respiratory samples without viral transport media, and the nasal collection allows for an easy and comfortable collection. Viral samples can be released directly into a small amount of saline, providing sample concentration of 30x or greater, providing greater standardization and improving downstream assay reliability. The product provides an immediate impact to increasing COVID testing efficiencies while being applicable to broader respiratory viral, bacterial, and genetic testing using the polymerase chain reaction (PCR) and next generation sequencing (NGS). The RHINOstic product is registered as Class I exempt medical device with the FDA and is available for purchase. To learn more, visit https://www.rhinostics.com .
All trademarks are owned and/or registered by Hamilton Company or Rhinostics in the U.S. and/or other countries. For details visit www.hamiltoncompany.com/trademarks .
Please send reader inquiries about this release directly to marketingrequest@hamiltoncompany.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005022/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom